Clinical Trial Participation

Selected news for the healthcare topic - Clinical Trial Participation, collected since 11/2017. This healthcare topic shares news with Genentech, Rare Diseases, Clinical Research, Food and Drug Administration and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
11/29/2021 A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems docwirenews.com ... group recently surveyed the clinical trial landscape in pancreatic adenocarcinoma and identified 430 active trials. These represent an opportunity to expand treatment options for patients with pancreatic adenocarcinoma. Our primary objective was to detail clinical trial participation among patients with pancreatic adenocarcinoma. Our secondary objective was to evaluate survival.Methods: We queried the National Cancer Database (2004–2016) for patients with pancreatic adenocarcinoma. Patients were stratified by trial participation: clinical ...
9/22/2021 Janice Krieger Receives $2.1 Million Grant to Use Virtual Human Technology to Promote Clinical Trial Participation Among Older Adult Minorities ufl.edu Janice Krieger Receives $2.1 Million Grant to Use Virtual Human Technology to Promote Clinical Trial Participation Among Older Adult Minorities Janice Krieger , University of Florida College of Journalism and Communications STEM Translational Communication Center director, and a team of researchers has been awarded a National Institute on Aging (NIA) grant to use the virtual health assistant ALEX (Agent Leveraging Empathy for eXams) to recruit older adult minorities for clinical trials ...
9/16/2021 Changing Cancer Research To Increase Equity thelcn.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity gallatinnews.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity murfreesboropost.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity southerndigest.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity baycitytribune.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity robertsoncountyconnection.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity theportlandsun.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity wilsonpost.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity hendersonvillestandard.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/16/2021 Changing Cancer Research To Increase Equity dnews.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/14/2021 Labcorp Teams with Oncology Research Startup to Eliminate Demographic Disparities in Cancer Treatment - G2 Intelligence g2intelligence.com ... and Precision OncologyA 2020 American Association for Cancer Research report on cancer disparities estimates that 34 percent of cancer deaths among US adults age 25 to 74 could be prevented if disparities in clinical trial participation were actively addressed.National Comprehensive Cancer Network guidelines recommend clinical trials as a treatment option for cancer. However, less than 5 percent of patients diagnosed with cancer are enrolled in trials. Reasons for ...
9/14/2021 Changing Cancer Research To Increase Equity communityq.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/14/2021 Changing Cancer Research To Increase Equity sewardindependent.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/14/2021 Changing Cancer Research To Increase Equity communityq.com ... is addressed. Now, more than ever, better understanding of the role of biology in cancer treatment, advances in precision treatment, and development of new technologies demands that we also make significant improvements in diverse clinical trial participation ,” explained SU2C CEO Sung Poblete, PhD, RN. What’s Being Done SU2C is collaborating with a number of industry leaders who are also committed to improving cancer disparities, including Genentech, Exact Sciences ...
9/10/2021 Group Focuses on Rare Disease Clinical Trial Participation rettsyndromenews.com Group Focuses on Rare Disease Clinical Trial Participation Participation in clinical trials exposes rare disease patients to financial, physical, and emotional pressures, according to the results of a patient focus group series. “Rare disease trial participants are running an endurance race they are highly motivated to complete, but these incremental burdens negatively impact their ability or willingness to enroll or remain in clinical trials,” KimberLee Heidmann, vice president of ...
9/10/2021 Group Focuses on Rare Disease Clinical Trial Participation sclerodermanews.com Group Focuses on Rare Disease Clinical Trial Participation Participation in clinical trials exposes rare disease patients to financial, physical, and emotional pressures, according to the results of a patient focus group series. “Rare disease trial participants are running an endurance race they are highly motivated to complete, but these incremental burdens negatively impact their ability or willingness to enroll or remain in clinical trials,” KimberLee Heidmann, vice president of ...
9/10/2021 Group Focuses on Rare Disease Clinical Trial Participation angelmansyndromenews.com Group Focuses on Rare Disease Clinical Trial Participation Participation in clinical trials exposes rare disease patients to financial, physical, and emotional pressures, according to the results of a patient focus group series. “Rare disease trial participants are running an endurance race they are highly motivated to complete, but these incremental burdens negatively impact their ability or willingness to enroll or remain in clinical trials,” KimberLee Heidmann, vice president of ...
9/10/2021 Group Focuses on Rare Disease Clinical Trial Participation sicklecellanemianews.com Group Focuses on Rare Disease Clinical Trial Participation Participation in clinical trials exposes rare disease patients to financial, physical, and emotional pressures, according to the results of a patient focus group series. “Rare disease trial participants are running an endurance race they are highly motivated to complete, but these incremental burdens negatively impact their ability or willingness to enroll or remain in clinical trials,” KimberLee Heidmann, vice president of ...